Sign In
Buy BIO
$304.83
-1.30 (-0.425%)
At Close: Jun 03, 2026
Exchange Traded Concepts LLC Buys 7,648 Shares of Bio-Rad Laboratories, Inc. $BIO
04:08am, Wednesday, 24'th Dec 2025
Exchange Traded Concepts LLC lifted its position in Bio-Rad Laboratories, Inc. (NYSE: BIO) by 54.9% in the undefined quarter, according to its most recent 13F filing with the SEC. The institutional in
Texas Permanent School Fund Corp Lowers Position in Bio-Rad Laboratories, Inc. $BIO
05:20am, Monday, 22'nd Dec 2025
Texas Permanent School Fund Corp reduced its position in shares of Bio-Rad Laboratories, Inc. (NYSE: BIO) by 17.8% during the second quarter, according to its most recent disclosure with the Securitie
Federated Hermes Inc. Has $30.66 Million Position in Bio-Rad Laboratories, Inc. $BIO
04:32am, Wednesday, 10'th Dec 2025
Federated Hermes Inc. lowered its stake in shares of Bio-Rad Laboratories, Inc. (NYSE: BIO) by 9.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Comm
Ariel Investments LLC Has $197.55 Million Stock Holdings in Bio-Rad Laboratories, Inc. $BIO
03:28am, Wednesday, 10'th Dec 2025
Ariel Investments LLC boosted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE: BIO) by 13.0% during the second quarter, according to its most recent 13F filing with the Securities and Excha
Fisher Asset Management LLC Sells 5,884 Shares of Bio-Rad Laboratories, Inc. $BIO
04:34am, Wednesday, 03'rd Dec 2025
Fisher Asset Management LLC lowered its position in shares of Bio-Rad Laboratories, Inc. (NYSE: BIO) by 4.1% during the second quarter, according to its most recent disclosure with the Securities and
JUPITER, Fla. and WAGENINGEN, Netherlands, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”), a global biotechnology company producing precision-engineered, animal-free prot
Artisan Partners Limited Partnership Sells 1,670 Shares of Bio-Rad Laboratories, Inc. $BIO
03:56am, Saturday, 22'nd Nov 2025
Artisan Partners Limited Partnership cut its holdings in Bio-Rad Laboratories, Inc. (NYSE: BIO) by 1.4% in the undefined quarter, according to the company in its most recent filing with the Securities
Digital Identity & Biometric Access Management Provider BIO-key (Nasdaq:BKYI) Reports Q3 Results; Enhanced Post Quarter Balance Sheet Supports 2026 Growth.
BIO-key (BKYI) Partners with VaporVM to Expand Reach of Advanced Identity & Access Management and Biometric Cybersecurity Solutions in Middle East, Africa.
BIO-key Showcases Biometric Identity Innovations at Africa Tech Festival 2025, November 10-13
04:01am, Monday, 10'th Nov 2025
BIO-key (Nasdaq: BKYI) Showcases Biometric Identity Innovations at Africa Tech Festival 2025, November 10-13 at the Cape Town Convention Centre, Booth H72.
Digital Identity and Biometric Solutions Provider BIO-key Hosts Q3 Investor Call Friday, November 14th at 10am ET
02:25pm, Friday, 07'th Nov 2025
Digital Identity and Biometric Solutions Provider BIO-key (Nasdaq: BKYI) Hosts Q3 Investor Call Friday, November 14th at 10am ET. Dial-in: 1-877-418-5460.
BIO-key Secures Significant Identity and Biometric Security Deployment with a Major Middle East Defense Sector Organisation
04:00am, Friday, 07'th Nov 2025
HOLMDEL, N.J. and RIYADH, Saudi Arabia, Nov. 07, 2025 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (NASDAQ: BKYI), a global leader in Identity and Access Management (IAM) and biometric authenticati
BIO-TECHNE DECLARES DIVIDEND
06:30am, Wednesday, 05'th Nov 2025
MINNEAPOLIS , Nov. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September
Why Bio-Rad Laboratories Stock Slipped by More Than 3% on Thursday
05:17pm, Thursday, 30'th Oct 2025
The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low.
Bio-Rad's Q3 Earnings Miss Estimates, Revenues Surpass, Stock Falls
10:06am, Thursday, 30'th Oct 2025
BIO's Q3 earnings fall short of estimates despite higher revenues, as margin pressure and weak research demand weigh on results.
